This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Already thriving with a successful launch of infused Vyvgart and its subcutaneou...
Human medicines European public assessment report (EPAR): Cinqaero, reslizumab, ...
Human medicines European public assessment report (EPAR): Edurant, rilpivirine, ...
After Pfizer let limited patient interest get the best of its hemophilia B gene ...
Human medicines European public assessment report (EPAR): Effentora, fentanyl, D...
The market turbulence unleashed by President Donald Trump’s tariff policies will...
A special congressional committee has recommended a $15 billion investment to bo...
Human medicines European public assessment report (EPAR): Fabhalta, Iptacopan, D...
As work continues on a new biologics plant in the U.S., Kyowa Kirin has complete...
Template for the qualified person's (QP) declaration concerning good manufacturi...
In today's Morning Rounds newsletter, RFK Jr.'s latest theory about vaccines, ho...
Questions & answers - Practical arrangements on the companion diagnostics consul...
Overview of NCAs participating in the voluntary Simultaneous National Scientific...
Questions & answers - Practical arrangements on the companion diagnostics consul...
While FDA drug and device reviewers and inspectors were protected from layoffs, ...
In this week’s episode of "The Top Line," Fierce Deputy Editor Andrea Park and F...
PhRMA's latest ad highlights the double trouble that can come from pharmacy bene...
Opinion on medicine for use outside EU: Aluvia, lopinavir,ritonavir, HIV Infecti...
Human medicines European public assessment report (EPAR): Xermelo, telotristat e...
Veterinary medicines European public assessment report (EPAR): Nobilis Multriva ...
Veterinary medicines European public assessment report (EPAR): Nobilis Multriva ...
Veterinary medicines European public assessment report (EPAR): Emevet, maropitan...
CVMP opinions on veterinary medicinal productsThe Committee adopted by consensus...